---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-26-000291"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:44:36.333723+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncology Institute Q4 revenue up 41.6% to $142M, net loss narrows to $7.5M

## Summary
- Q4 2025 revenue $142.0M (+41.6% YoY); gross profit $22.7M (+55.2%).
- Net loss narrowed to $7.5M from $13.2M; adj EBITDA improved to $147K from -$7.8M.
- FY2025 revenue $502.7M (+27.8%); net loss $60.6M vs $64.7M; adj EBITDA -$12.4M vs -$35.7M.
- Added 9 new capitated contracts in CA, FL, NV covering ~260K lives; expanded Elevance, Humana, CarePlus partnerships.
- Cash from operations positive $3.2M in Q4; cash balance $33.6M at year-end.

## SEC filing metadata
- accession: 0001079973-26-000291
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000291/0001079973-26-000291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000291/toi_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-26-000291
- JSON: https://secwatch.observer/filing/0001079973-26-000291.json
- Plain text: https://secwatch.observer/filing/0001079973-26-000291.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.